Medtronic Reports Results of Resolute Onyx DES in Onyx ONE Global Study for High-Bleeding Risk Patients with One-Month DAPT
Shots:
- The Onyx ONE global study involves assessing of Resolute Onyx DES vs Biosensor International's BioFreedom DCS in ~2000 high bleeding risk patients with one month of dual antiplatelet therapy (DAPT)
- The Onyx ONE global study results: met its 1EPs of cardiac death- MI & ST @1yr. showing non-inferiority to comparator stent; acute performance with device success rate (92.8% vs 89.7%); Low LTR (2.8% vs 4.0%); ST (1.3% vs 2.1%); rate of the composite adverse event endpoint @1yr. (7.5% vs 8.8%) including lower MI events (4.3% vs 6.8%)
- The Resolute Onyx drug-eluting stent is an advanced workhorse DES for coronary diseases- heals vessels with its BioLinx polymer and Continuous Sinusoid Technology (CST) and has received CE mark & FDA’s approval in Sept’2014 & Apr’2017 respectively
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Wearable Technology
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com